|

KYV-101 anti-CD19 CAR-T cell therapy Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Stanford University1

Indications

  • Multiple Sclerosis, Secondary Progressive1
  • Multiple Sclerosis, Primary Progressive1
  • Multiple Sclerosis1

Palo Alto, California1 trial

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Stanford Multiple Sclerosis Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.